Dana Small Cap Equity
As of: August 29, 2018
Dana Epiphany ESG Small Cap Equity Fund
Fund Information
as of 9/30/21
| SYMBOL | DSCIX |
| INCEPTION DATE | 11/2/15 |
| BENCHMARK | Russell 2000 Index |
| TOTAL FUND AUM | $16.5 MM |
| TOTAL FIRM AUM | $7.3 BN |
| MIN. INVESTMENT | $5,000 |
| NET EXPENSE RATIO | 0.95% |
| GROSS EXPENSE RATIO | 1.88% |
| NUMBER OF HOLDINGS | 60 – 65 |
| TARGET CASH POSITION | 0 – 1% |
| INDIVIDUAL SECURITY LIMIT | < 4% |
| SECTOR LIMITS | SECTOR NEUTRAL |
Data source: Morningstar Direct; The Adviser has contractually agreed to waive its management fee and/or reimburse certain operating expenses through 2/28/2022, so that Total Annual Operating Expenses does not exceed 0.95% for the Fund. Time period for statistical calculations is from fund inception to 6/30/21.
Top Holdings
as of 9/30/21, subject to change. Current and future portfolio holdings are subject to risk.
| Ovintiv, Inc. | 2.33% |
| Horizon Therapeutics PLC | 2.33% |
| Blueprint Medicines Corp | 2.16% |
| Omnicell, Inc. | 2.15% |
| Group 1 Automotive, Inc. | 2.15% |
| Perficient, Inc. | 2.09% |
| Envista Holdings Corp | 2.08% |
| CONMED Corp | 2.07% |
| Rexnord Corp | 2.06% |
| Aurinia Pharmaceuticals, Inc. | 2.04% |